Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (15759)
All Articles published online
|
Publishing Process of This Article
|
Jul 16, 2015 (publication date) through Feb 21, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases 2015; 3(7): 545-555 [PMID: 26244148 DOI: 10.12998/wjcc.v3.i7.545] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v3/i7/545.htm |
| Number | Citing Articles |
| 1 |
A. Di Biase, L. Attorri, R. Di Benedetto, S. Salvati. Nutrition and Lifestyle in Neurological Autoimmune Diseases. 2017; : 267 doi: 10.1016/B978-0-12-805298-3.00027-X
|
| 2 |
Chi T. L. Truong, Hoa V. Le, Aaron W. Kamauu, John R. Holmen, Christopher L. Fillmore, Monica G. Kobayashi, Schiffon L. Wong. Creating a Real-World Data, United States Healthcare Claims-Based Adaptation of Kurtzke Functional Systems Scores for Assessing Multiple Sclerosis Severity and Progression. Advances in Therapy 2021; 38(9): 4786 doi: 10.1007/s12325-021-01858-9
|
| 3 |
Gary Cutter, Antonella Veneziano, Augusto Grinspan, Mahir Al-Banna, Alexey Boyko, Maria Zakharova, Eva Maida, Marija Bosnjak Pasic, Sanjay K. Gandhi, Robin Everts, Cinzia Cordioli, Silvia Rossi. Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS. Multiple Sclerosis and Related Disorders 2019; 33: 13 doi: 10.1016/j.msard.2019.04.036
|
| 4 |
Ieva Eskyte, Ana Manzano, George Pepper, Sue Pavitt, Helen Ford, Hilary Bekker, Jeremy Chataway, Klaus Schmierer, David Meads, Edward Webb, Barbara Potrata. Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis. Multiple Sclerosis and Related Disorders 2019; 27: 370 doi: 10.1016/j.msard.2018.11.016
|
| 5 |
Giancarlo Comi, Raed Alroughani, Aaron L Boster, Ann D Bass, Regina Berkovich, Óscar Fernández, Ho Jin Kim, Volker Limmroth, Jan Lycke, Richard AL Macdonell, Basil Sharrack, Barry A Singer, Patrick Vermersch, Heinz Wiendl, Tjalf Ziemssen, Alan Jacobs, Nadia Daizadeh, Claudio E Rodriguez, Anthony Traboulsee, Darren P. Baker, Ericka M. Bueno, Colin Mitchell, Rebecca L. Orndorff, Valerie P. Zediak. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Multiple Sclerosis Journal 2020; 26(14): 1866 doi: 10.1177/1352458519888610
|
| 6 |
Francesco Corallo, Lilla Bonanno, Marcella Di Cara, Carmela Rifici, Edoardo Sessa, GianGaetano D’Aleo, Viviana Lo Buono, Giuseppe Venuti, Placido Bramanti, Silvia Marino. Therapeutic adherence and coping strategies in patients with multiple sclerosis. Medicine 2019; 98(29): e16532 doi: 10.1097/MD.0000000000016532
|
| 7 |
Francois Grand’Maison, Michael Yeung, Sarah A. Morrow, Liesly Lee, Francois Emond, Brian J. Ward, Pierre Laneuville, Robyn Schecter. Sequencing of disease-modifying therapies for relapsing–remitting multiple sclerosis: a theoretical approach to optimizing treatment. Current Medical Research and Opinion 2018; 34(8): 1419 doi: 10.1080/03007995.2018.1458023
|
| 8 |
Roua A. Nouh, Ahmed Kamal, Oluwaseyi Oyewole, Walaa A. Abbas, Bishoy Abib, Abdelrouf Omar, Somaia T. Mansour, Anwar Abdelnaser. Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine. Pharmaceutics 2024; 16(2): 241 doi: 10.3390/pharmaceutics16020241
|
| 9 |
Emanuele D’Amico, Clara G Chisari, Lara Gitto, Aurora Zanghì, Simona Toscano, Francesco Patti. Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opinion on Pharmacotherapy 2019; 20(11): 1331 doi: 10.1080/14656566.2019.1615880
|
| 10 |
Alfadil Haroon, Syed Osman Ahmed, Mahmoud Aljurf, Etedal AbuElbasher, Hazzaa Alzahrani. Co-occurrence of Multiple Sclerosis and Severe Aplastic Anemia: A Report of Two Cases Successfully Treated with Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Hematology International 2023; 5(2-3): 61 doi: 10.1007/s44228-023-00028-8
|
| 11 |
M Pazhouhandeh, M-A Sahraian, S D Siadat, A Fateh, F Vaziri, F Tabrizi, F Ajorloo, A K Arshadi, E Fatemi, S Piri Gavgani, F Mahboudi, F Rahimi Jamnani. A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patients. Clinical and Experimental Immunology 2018; 192(1): 18 doi: 10.1111/cei.13087
|
| 12 |
|
| 13 |
Tan Guojun, Xu Yan, Wang Weizhi, Wang Lihua, Li Chunyang, Zhang Xinghu, Zhou Hongyu, Dong Huiqing, Zhang Meini, Jin Tao, Yang Huan, Cui Liying, Guo Li. A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China. Multiple Sclerosis and Related Disorders 2022; 60: 103732 doi: 10.1016/j.msard.2022.103732
|
| 14 |
Najme Dastani, Ali Arab, Heidar Raissi. DFT computational study towards investigating Cladribine anticancer drug adsorption on the graphene and functionalized graphene. Structural Chemistry 2020; 31(5): 1691 doi: 10.1007/s11224-020-01526-8
|
| 15 |
Niklas Frahm, David Ellenberger, Alexander Stahmann, Firas Fneish, Daniel Lüftenegger, Hans C. Salmen, Ksenija Schirduan, Tom P. A. Schaak, Peter Flachenecker, Christoph Kleinschnitz, Friedemann Paul, Dagmar Krefting, Uwe K. Zettl, Melanie Peters, Clemens Warnke. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry. Therapeutic Advances in Neurological Disorders 2024; 17 doi: 10.1177/17562864241239740
|
| 16 |
Ramón Villaverde-González, Antonio Candeliere-Merlicco, María Aránzazu Alonso-Frías, Eladio Aparicio Castro, Andrés Carrillo Alcaraz, Javier Mallada Frechín, Ángel Pérez Sempere. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study. Multiple Sclerosis and Related Disorders 2020; 46: 102518 doi: 10.1016/j.msard.2020.102518
|
| 17 |
Mark S. Freedman, Daniel Selchen, Alexandre Prat, Paul S. Giacomini. Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 2018; 45(5): 489 doi: 10.1017/cjn.2018.17
|
| 18 |
Vishnu Prathapan, Peter Eipert, Nicole Wigger, Markus Kipp, Revathi Appali, Oliver Schmitt. Modeling and simulation for prediction of multiple sclerosis progression. Computers in Biology and Medicine 2024; 175: 108416 doi: 10.1016/j.compbiomed.2024.108416
|
| 19 |
Hussain Abdulrahman Al-Omar, Nada Alsowaida, Lama Aldosari, Ahmed Mayet, Reem Bunyan, Mohammed Aljumah. Exploring physicians’ prescribing behavior in patients with multiple sclerosis in Saudi Arabia: a sequential explanatory mixed-methods. BMC Neurology 2023; 23(1) doi: 10.1186/s12883-023-03184-9
|
| 20 |
Margo I. Jansen, Yasir Mahmood, Jordan Lee, Sarah Thomas Broome, James A. Waschek, Alessandro Castorina. Targeting the PAC1 receptor mitigates degradation of myelin and synaptic markers and diminishes locomotor deficits in the cuprizone demyelination model. Journal of Neurochemistry 2024; 168(9): 3250 doi: 10.1111/jnc.16199
|
| 21 |
Tutut Habibah, Jana Matonohová, Jaromír Kulhánek, Una Fitzgerald, Marek Ingr, Martin Pravda, Abhay Pandit, Vladimír Velebný. In situ formed aldehyde-modified hyaluronic acid hydrogel with polyelectrolyte complexes of aldehyde-modified chondroitin sulfate and gelatin: An approach for minocycline delivery. Carbohydrate Polymers 2024; 343: 122455 doi: 10.1016/j.carbpol.2024.122455
|
| 22 |
Joshua Mardan, Mohammad Akhtar Hussain, Michelle Allan, Lisa B Grech. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. Journal of Managed Care & Specialty Pharmacy 2021; 27(9): 1273 doi: 10.18553/jmcp.2021.27.9.1273
|
| 23 |
Ann D. Bass, Rafael Arroyo, Aaron L. Boster, Alexey N. Boyko, Sara Eichau, Carolina Ionete, Volker Limmroth, Carlos Navas, Daniel Pelletier, Carlo Pozzilli, Jennifer Ravenscroft, Livia Sousa, Mar Tintoré, Bernard M.J. Uitdehaag, Darren P. Baker, Nadia Daizadeh, Zia Choudhry, David Rog. Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Multiple Sclerosis and Related Disorders 2021; 49: 102717 doi: 10.1016/j.msard.2020.102717
|
| 24 |
Andrea Tacchino, Giampaolo Brichetto, Paola Zaratin, Mario Alberto Battaglia, Michela Ponzio. Multiple sclerosis and rehabilitation: an overview of the different rehabilitation settings. Neurological Sciences 2017; 38(12): 2131 doi: 10.1007/s10072-017-3110-7
|
| 25 |
Sarah El-Wahsh, Claire Layfield, Hans Bogaardt, Fiona Kumfor, Kirrie J. Ballard. Perspectives from the patient: A content analysis of communication changes, impact, and strategies to facilitate communication in multiple sclerosis. International Journal of Speech-Language Pathology 2022; 24(2): 173 doi: 10.1080/17549507.2021.1973101
|
| 26 |
Kelly Jean Dickerson. Prognostic uncertainty in multiple sclerosis: A concept analysis. Journal of Clinical Nursing 2023; 32(3-4): 633 doi: 10.1111/jocn.16069
|
| 27 |
B. Bourre, O. Casez, J. Ciron, A. Gueguen, A. Kwiatkowski, X. Moisset, A. Montcuquet, X. Ayrignac. Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice. Revue Neurologique 2023; 179(4): 256 doi: 10.1016/j.neurol.2022.09.006
|
| 28 |
P. Chesi, M. G. Marini, G. L. Mancardi, F. Patti, L. Alivernini, A. Bisecco, G. Borriello, S. Bucello, F. Caleri, P. Cavalla, E. Cocco, C. Cordioli, M. Di Giuseppe, R. Fantozzi, M. Gattuso, F. Granella, M. Liguori, L. Locatelli, A. Lugaresi, S. Marangoni, L. Moiola, E. Mutta, W. Neri, L. Pastò, P. Perini, M. Petruzzo, K. Plewnia, A. M. Repice, M. Rezzonico, S. Romano, M. Rovaris, E. Sessa, C. Tortorella, R. Totaro, P. Valentino. Listening to the neurological teams for multiple sclerosis: the SMART project. Neurological Sciences 2020; 41(8): 2231 doi: 10.1007/s10072-020-04301-z
|
| 29 |
Yazed AlRuthia, Bander Balkhi, Sahar Abdullah Alkhalifah, Salman Aljarallah, Lama Almutairi, Miteb Alanazi, Abdulmalik Alajlan, Suliman M. Aldhafiri, Nuha M. Alkhawajah. Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia. International Journal of Environmental Research and Public Health 2021; 18(24): 13261 doi: 10.3390/ijerph182413261
|
| 30 |
Iro Triantafyllakou, Nausicaa Clemente, Ravi Kumar Khetavat, Umberto Dianzani, Theodore Tselios. Development of PLGA Nanoparticles with a Glycosylated Myelin Oligodendrocyte Glycoprotein Epitope (MOG35–55) against Experimental Autoimmune Encephalomyelitis (EAE). Molecular Pharmaceutics 2022; 19(11): 3795 doi: 10.1021/acs.molpharmaceut.2c00277
|
| 31 |
Ursula Muñoz, Cristina Sebal, Esther Escudero, Elena Urcelay, Rafael Arroyo, Maria A. García-Martínez, Francisco J. Quintana, Roberto Alvarez-Lafuente, María C. Sádaba. Serum IgM to Lipids Predicts the Response to Tysabri® and IFN-β in MS. SSRN Electronic Journal 2021; doi: 10.2139/ssrn.3928506
|
| 32 |
Yun-Liang Wang, Peng Xue, Chun-Yang Xu, Zhen Wang, Xin-Shan Liu, Lin-Lin Hua, Hong-Ying Bai, Zhi-Lei Zeng, Hai-Feng Duan, Jin-Feng Li. SPK1-transfected UCMSC has better therapeutic activity than UCMSC in the treatment of experimental autoimmune encephalomyelitis model of Multiple sclerosis. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-19703-5
|
| 33 |
Lauren B. Krupp, Maria Cecilia Vieira, Haley Toledano, Desi Peneva, Eric Druyts, Ping Wu, Fernanda C. Boulos. A Review of Available Treatments, Clinical Evidence, and Guidelines for Diagnosis and Treatment of Pediatric Multiple Sclerosis in the United States. Journal of Child Neurology 2019; 34(10): 612 doi: 10.1177/0883073819855592
|
| 34 |
Shujun Ge, Xi Jiang, Debayon Paul, Li Song, Xiaofang Wang, Joel S. Pachter. Human ES-derived MSCs correct TNF-α-mediated alterations in a blood–brain barrier model. Fluids and Barriers of the CNS 2019; 16(1) doi: 10.1186/s12987-019-0138-5
|
| 35 |
Najme Dastani, Ali Arab, Heidar Raissi. DFT study of Ni-doped graphene nanosheet as a drug carrier for multiple sclerosis drugs. Computational and Theoretical Chemistry 2021; 1196: 113114 doi: 10.1016/j.comptc.2020.113114
|
| 36 |
Yaron Ilan. Next-Generation Personalized Medicine: Implementation of Variability Patterns for Overcoming Drug Resistance in Chronic Diseases. Journal of Personalized Medicine 2022; 12(8): 1303 doi: 10.3390/jpm12081303
|
| 37 |
Gayathri Wijeweera, Nalaka Wijekoon, Lakmal Gonawala, Yoonus Imran, Chandra Mohan, K. Ranil D. De Silva, Min Li. Therapeutic Implications of Some Natural Products for Neuroimmune Diseases: A Narrative of Clinical Studies Review. Evidence-Based Complementary and Alternative Medicine 2023; 2023(1) doi: 10.1155/2023/5583996
|
| 38 |
Catharina J. A. Romme, Emma A. M. Stanley, Pauline Mouches, Matthias Wilms, G. Bruce Pike, Luanne M. Metz, Nils D. Forkert. Analysis and visualization of the effect of multiple sclerosis on biological brain age. Frontiers in Neurology 2024; 15 doi: 10.3389/fneur.2024.1423485
|
| 39 |
Nizameddin Koca, Meral Seferoğlu. Effects of disease-modifying therapies on lipid parameters in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders 2023; 77: 104876 doi: 10.1016/j.msard.2023.104876
|
| 40 |
Mansour A. Alharbi, Fahad Aldosari, Ahmed Hasan Althobaiti, Faris M. Abdullah, Salman Aljarallah, Nuha M. Alkhawajah, Miteb Alanazi, Yazed AlRuthia. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia. BMC Health Services Research 2023; 23(1) doi: 10.1186/s12913-023-09462-z
|
| 41 |
Michael Enders, Thorsten Heider, Andreas Ludwig, Stefanie Kuerten. Strategies for Neuroprotection in Multiple Sclerosis and the Role of Calcium. International Journal of Molecular Sciences 2020; 21(5): 1663 doi: 10.3390/ijms21051663
|
| 42 |
Elham Sardari, Ahmad Ebadi, Nima Razzaghi-Asl. In silico repurposing of CNS drugs for multiple sclerosis. Multiple Sclerosis and Related Disorders 2023; 73: 104622 doi: 10.1016/j.msard.2023.104622
|
| 43 |
Valentina Pegoretti, Kathryn A. Swanson, John R. Bethea, Lesley Probert, Ulrich L. M. Eisel, Roman Fischer. Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development. Oxidative Medicine and Cellular Longevity 2020; 2020: 1 doi: 10.1155/2020/7191080
|
| 44 |
Jelena Brasanac, Claudia Chien. A review on multiple sclerosis prognostic findings from imaging, inflammation, and mental health studies. Frontiers in Human Neuroscience 2023; 17 doi: 10.3389/fnhum.2023.1151531
|
| 45 |
Atefeh Rostami, Mostafa Robatjazi, Amir Dareyni, Ali Ramezan Ghorbani, Omid Ganji, Mahdiye Siyami, Amir Reza Raoofi. Enhancing classification of active and non-active lesions in multiple sclerosis: machine learning models and feature selection techniques. BMC Medical Imaging 2024; 24(1) doi: 10.1186/s12880-024-01528-6
|
| 46 |
Tetsuya Akaishi, Ichiro Nakashima. Efficiency of antibody therapy in demyelinating diseases. International Immunology 2017; 29(7): 327 doi: 10.1093/intimm/dxx037
|
| 47 |
Piotr Olejnik, Zuzanna Roszkowska, Sylwia Adamus, Kaja Kasarełło. Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects. Pharmacological Reports 2024; 76(5): 926 doi: 10.1007/s43440-024-00642-0
|
| 48 |
Riley Bove, Angela Applebee, Katrina Bawden, Celeste Fine, Anna Shah, Robin L Avila, Nicholas Belviso, Filipe Branco, Kinyee Fong, James B Lewin, Jieruo Liu, Sarah M England, Megan Vignos. Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis. Multiple Sclerosis and Related Disorders 2024; 88: 105738 doi: 10.1016/j.msard.2024.105738
|
| 49 |
Dragos Paul Mihai, Anca Ungurianu, Cosmin I. Ciotu, Michael J. M. Fischer, Octavian Tudorel Olaru, George Mihai Nitulescu, Corina Andrei, Cristina Elena Zbarcea, Anca Zanfirescu, Oana Cristina Seremet, Cornel Chirita, Simona Negres. Effects of Venlafaxine, Risperidone and Febuxostat on Cuprizone-Induced Demyelination, Behavioral Deficits and Oxidative Stress. International Journal of Molecular Sciences 2021; 22(13): 7183 doi: 10.3390/ijms22137183
|
| 50 |
Aaron E. Miller, Tomas P. Olsson, Jerry S. Wolinsky, Giancarlo Comi, Ludwig Kappos, Xueqiang Hu, Xianhao Xu, Alex L. Lublin, Philippe Truffinet, Jeffrey Chavin, Jean-Luc Delhay, Myriam Benamor, Annie Purvis, Mark S. Freedman. Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study. Multiple Sclerosis and Related Disorders 2020; 46: 102438 doi: 10.1016/j.msard.2020.102438
|
| 51 |
Jieni Li, Yinan Huang, George J. Hutton, Rajender R. Aparasu. Assessing treatment switch among patients with multiple sclerosis: A machine learning approach. Exploratory Research in Clinical and Social Pharmacy 2023; 11: 100307 doi: 10.1016/j.rcsop.2023.100307
|
| 52 |
Tjalf Ziemssen, Raimar Kern, Christian Cornelissen. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod. BMC Neurology 2016; 16(1) doi: 10.1186/s12883-016-0648-6
|
| 53 |
Hernan Inojosa, Undine Proschmann, Katja Akgün, Tjalf Ziemssen. The need for a strategic therapeutic approach: multiple sclerosis in check. Therapeutic Advances in Chronic Disease 2022; 13 doi: 10.1177/20406223211063032
|
| 54 |
Edgar J. Hernández-Flores, Moisés Manuel Gallardo-Pérez, Max Robles-Nasta, Merittzel Abigail Montes-Robles, Daniela Sánchez-Bonilla, María De Lourdes Pastelín-Martínez, Guillermo Ocaña-Ramm, Juan Carlos Olivares-Gazca, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles. Second Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis: A Single-Center Prospective Experience. Transplantation Proceedings 2024; 56(1): 211 doi: 10.1016/j.transproceed.2023.12.004
|
| 55 |
Emanuele D’Amico, Carmela Leone, Aurora Zanghì, Salvatore Lo Fermo, Francesco Patti. Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study. Journal of Neurology 2016; 263(9): 1802 doi: 10.1007/s00415-016-8207-z
|
| 56 |
Li Jiao, Shougang Guo. Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.966766
|
| 57 |
Helcio Alvarenga-Filho, Priscila M. Sacramento, Thais B. Ferreira, Joana Hygino, Jorge Eduardo Canto Abreu, Sonia Regina Carvalho, Ana Cristina Wing, Regina Maria Papais Alvarenga, Cleonice A.M. Bento. Combined exercise training reduces fatigue and modulates the cytokine profile of T-cells from multiple sclerosis patients in response to neuromediators. Journal of Neuroimmunology 2016; 293: 91 doi: 10.1016/j.jneuroim.2016.02.014
|
| 58 |
Ramón Villaverde-González. Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy. Degenerative Neurological and Neuromuscular Disease 2022; : 1 doi: 10.2147/DNND.S203406
|
| 59 |
Imtiaz A Samjoo, Evelyn Worthington, Christopher Drudge, Melody Zhao, Chris Cameron, Dieter A Häring, Dee Stoneman, Luisa Klotz, Nicholas Adlard. Efficacy classification of modern therapies in multiple sclerosis. Journal of Comparative Effectiveness Research 2021; 10(6): 495 doi: 10.2217/cer-2020-0267
|
| 60 |
Miceline Mésidor, Marie‐Claude Rousseau, Pierre Duquette, Marie‐Pierre Sylvestre. Classification and visualization of longitudinal patterns of medication dose: An application to interferon‐beta‐1a and amitriptyline in patients with multiple sclerosis. Pharmacoepidemiology and Drug Safety 2021; 30(9): 1214 doi: 10.1002/pds.5297
|
| 61 |
Roberto De Masi, Stefania Orlando. IFI35 as a biomolecular marker of neuroinflammation and treatment response in multiple sclerosis. Life Sciences 2020; 259: 118233 doi: 10.1016/j.lfs.2020.118233
|
| 62 |
Nathallie George, Cledervern Brebnor Des Isles, Ghazal Tannous. New-Onset Multiple Sclerosis in Pregnancy: Diagnostic Approaches and Treatment Dilemmas. Cureus 2024; doi: 10.7759/cureus.74685
|
| 63 |
Weipeng Wei, Denglei Ma, Lin Li, Lan Zhang. Progress in the Application of Drugs for the Treatment of Multiple Sclerosis. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.724718
|
| 64 |
Miranda Z. Kozlicki, Brandon Markley, Nisha B. Shah, Josh DeClercq, Leena Choi, Autumn D. Zuckerman. A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy. Multiple Sclerosis and Related Disorders 2022; 63: 103860 doi: 10.1016/j.msard.2022.103860
|
| 65 |
James B.W. Hilton, Kai Kysenius, Jeffrey R. Liddell, Stephen W. Mercer, Carsten Rautengarten, Dominic J. Hare, Gojko Buncic, Bence Paul, Simon S. Murray, Catriona A. McLean, Trevor J. Kilpatrick, Joseph S. Beckman, Scott Ayton, Ashley I. Bush, Anthony R. White, Blaine R. Roberts, Paul S. Donnelly, Peter J. Crouch. Integrated elemental analysis supports targeting copper perturbations as a therapeutic strategy in multiple sclerosis. Neurotherapeutics 2024; 21(5): e00432 doi: 10.1016/j.neurot.2024.e00432
|
| 66 |
Guang-Xian Zhang. Neuroimmune Pharmacology and Therapeutics. 2024; : 599 doi: 10.1007/978-3-031-68237-7_35
|
| 67 |
Nazire Pinar Acar Ozen, Ece Gok Dursun, Asli Tuncer, Rana Karabudak. Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care. Multiple Sclerosis and Related Disorders 2024; 84: 105503 doi: 10.1016/j.msard.2024.105503
|
| 68 |
Mohammad Ehsanul Karim, Fabio Pellegrini, Robert W Platt, Gabrielle Simoneau, Julie Rouette, Carl de Moor. The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review. Multiple Sclerosis Journal 2022; 28(9): 1317 doi: 10.1177/1352458520972557
|
| 69 |
Nasrin Abulhasanbeigi Gallehzan, Majid Khosravi, Khosro Jamebozorgi, Nazanin Mir, Habib Jalilian, Samira Soleimanpour, Saeed Hoseini, Aziz Rezapour, Abbas Eshraghi. Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review. Health Economics Review 2024; 14(1) doi: 10.1186/s13561-024-00478-7
|
| 70 |
Hernan Inojosa, Tjalf Ziemssen. Handbook of Imaging in Multiple Sclerosis. 2025; : 71 doi: 10.1016/B978-0-323-95739-7.00004-6
|
| 71 |
Alastair Watson, C. Mirella Spalluto, Christopher McCrae, Doriana Cellura, Hannah Burke, Danen Cunoosamy, Anna Freeman, Alex Hicks, Michael Hühn, Kristoffer Ostridge, Karl J. Staples, Outi Vaarala, Tom Wilkinson. Dynamics of IFN-β Responses during Respiratory Viral Infection. Insights for Therapeutic Strategies. American Journal of Respiratory and Critical Care Medicine 2020; 201(1): 83 doi: 10.1164/rccm.201901-0214OC
|
| 72 |
Jagadeswara R. Earla, Rutugandha Paranjpe, Nandita Kachru, George J. Hutton, Rajender R. Aparasu. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Research in Social and Administrative Pharmacy 2020; 16(12): 1670 doi: 10.1016/j.sapharm.2020.02.016
|
| 73 |
Hayder K. Hassoun, Anmar Oday Hatem, Akram Al-Mahdawi, Sarwer Jamal Al-Bajalan, Ali Kadim Karim, Sarmad Abdulrasool Al-Mashta, Saif Mohammed Tawfeeq, Majeed Salih Hamad, Nawfal M. Sheaheed, Samer Mohammed Ridha, Murad Al-Naqshbandi, Hasan Aziz Al-Hamadani. Iraqi experts consensus on the management of relapsing remitting multiple sclerosis in adults. Current Medical Research and Opinion 2024; 40(6): 947 doi: 10.1080/03007995.2024.2339938
|
| 74 |
T. Ziemssen, D. Rothenbacher, J. Kuhle, T. Berger. Real-world-Evidenz. Der Nervenarzt 2017; 88(10): 1153 doi: 10.1007/s00115-017-0387-y
|
| 75 |
Norma Deri, Andres Barboza, Carlos Vrech, Roberto Rey, Marcos Burgos, Marcela Fiol, Cristian CalvoVildoso, Liliana Patrucco, Gustavo Jose, Paula Aliberti, Daniela Chirico, Maria B. Federico, Gustavo Seifer, Raul Piedrabuena. Clinical characterization of long-term multiple sclerosis (COLuMbus) patients in Argentina: A cross-sectional non-interventional study. Multiple Sclerosis and Related Disorders 2024; 83: 105421 doi: 10.1016/j.msard.2023.105421
|
| 76 |
Cindy Neunert, Roula Farah, Joanne Yacobovich, Ellis Neufeld. Refractory autoimmune disease: an overview of when first-line therapy is not enough. Seminars in Hematology 2016; 53: S35 doi: 10.1053/j.seminhematol.2016.04.011
|
| 77 |
Peter Morin, Mingfei Li, Ying Wang, Byron J. Aguilar, Dan Berlowitz, Amir Abbas Tahami Monfared, Michael Irizarry, Quanwu Zhang, Weiming Xia. Clinical Staging of Alzheimer’s Disease: Concordance of Subjective and Objective Assessments in the Veteran’s Affairs Healthcare System. Neurology and Therapy 2022; 11(3): 1341 doi: 10.1007/s40120-022-00379-z
|
| 78 |
Giorgia Maniscalco, Vincenzo Brescia Morra, Ciro Florio, Giacomo Lus, Gioacchino Tedeschi, Maddalena Cianfrani, Renato Docimo, Stefania Miniello, Felice Romano, Leonardo Sinisi, Daniele Spitaleri, Giuseppe Longo, Ugo Trama, Maria Triassi, Cristina Scavone, Annalisa Capuano. Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project. Pharmaceuticals 2020; 13(12): 466 doi: 10.3390/ph13120466
|
| 79 |
Bonaventura Casanova, Carlos Quintanilla-Bordás, Francisco Gascón. Escalation vs. Early Intense Therapy in Multiple Sclerosis. Journal of Personalized Medicine 2022; 12(1): 119 doi: 10.3390/jpm12010119
|
| 80 |
Imane Charmarke-Askar, Caroline Spenlé, Dominique Bagnard. Complementary strategies to be used in conjunction with animal models for multiple sclerosis drug discovery: adapting preclinical validation of drug candidates to the need of remyelinating strategies. Expert Opinion on Drug Discovery 2024; 19(9): 1115 doi: 10.1080/17460441.2024.2382180
|
| 81 |
Thor Ameri Chalmer, Tomas Kalincik, Bjarne Laursen, Per Soelberg Sorensen, Melinda Magyari. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy. Journal of Neurology 2019; 266(2): 306 doi: 10.1007/s00415-018-9126-y
|
| 82 |
Sharmim Sultana, Thanh Doan Viet, Tasmiha Amin, Esha Kazi, Luigina Micolucci, Abul Kalam Mohammad Moniruzzaman Mollah, Most Mauluda Akhtar, Md Soriful Islam. Exploring Inflammasome Complex as a Therapeutic Approach in Inflammatory Diseases. Future Pharmacology 2023; 3(4): 789 doi: 10.3390/futurepharmacol3040048
|
| 83 |
Marita Zimmermann, Elizabeth Brouwer, Jeffrey A. Tice, Matt Seidner, Anne M. Loos, Shanshan Liu, Richard H. Chapman, Varun Kumar, Josh J. Carlson. Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. CNS Drugs 2018; 32(12): 1145 doi: 10.1007/s40263-018-0566-9
|
| 84 |
Volkan Dericioğlu, Semra Akkaya Turhan, Halit Eren Erdem, Mehmet Orkun Sevik, Esra Erdil, Gülin Sünter, Kadriye Ağan, Ebru Toker. In Vivo Corneal Confocal Microscopy in Multiple Sclerosis: Can it Differentiate Disease Relapse in Multiple Sclerosis?. American Journal of Ophthalmology 2023; 250: 138 doi: 10.1016/j.ajo.2023.01.015
|
| 85 |
Chiara Zecca, Giulio Disanto, Rosaria Sacco, Gianna C. Riccitelli, Claudio Gobbi. Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients. BMC Neurology 2019; 19(1) doi: 10.1186/s12883-019-1383-6
|
| 86 |
Dragos Paul Mihai, George Mihai Nitulescu, George Nicolae Daniel Ion, Cosmin Ionut Ciotu, Cornel Chirita, Simona Negres. Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel as a Potential Therapeutic Solution for Multiple Sclerosis. Pharmaceutics 2019; 11(9): 446 doi: 10.3390/pharmaceutics11090446
|
| 87 |
Nora Welsh, Krista Disano, Michael Linzey, Steven C. Pike, Andrew D. Smith, Andrew R. Pachner, Francesca Gilli. CXCL10/IgG1 Axis in Multiple Sclerosis as a Potential Predictive Biomarker of Disease Activity. Neurology Neuroimmunology & Neuroinflammation 2024; 11(2) doi: 10.1212/NXI.0000000000200200
|
| 88 |
Qianye Zhang, Wei Sun, Qingpeng Wang, Xuexing Zheng, Ruiyan Zhang, Ning Zhang. A High MCT‐Based Ketogenic Diet Suppresses Th1 and Th17 Responses to Ameliorate Experimental Autoimmune Encephalomyelitis in Mice by Inhibiting GSDMD and JAK2‐STAT3/4 Pathways. Molecular Nutrition & Food Research 2024; 68(3) doi: 10.1002/mnfr.202300602
|
| 89 |
Ahmad Mehdipour, Ayyub Ebrahimi, Mohammad-Reza Shiri-Shahsavar, Jafar Soleimani-Rad, Leila Roshangar, Mohammad Samiei, Abbas Ebrahimi-Kalan. The potentials of umbilical cord-derived mesenchymal stem cells in the treatment of multiple sclerosis. Reviews in the Neurosciences 2019; 30(8): 857 doi: 10.1515/revneuro-2018-0057
|
| 90 |
Thais Fernanda de Campos Fraga-Silva, Luiza Ayumi Nishiyama Mimura, Larissa Ragozo Cardoso de Oliveira, Juliana Helena dos Santos Toledo, Patrícia Aparecida Borim, Sofia Fernanda Gonçalvez Zorzella-Pezavento, Diego Peres Alonso, Paulo Eduardo Martins Ribolla, Carlos Alberto Ferreira de Oliveira, Denise Morais da Fonseca, Eduardo J. Villablanca, Alexandrina Sartori. Selenization of S. cerevisiae increases its protective potential in experimental autoimmune encephalomyelitis by triggering an intestinal immunomodulatory loop. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-79102-7
|
| 91 |
Katherine Julian, Jaime Imitola. Current Progress in iPSC Disease Modeling. 2022; : 31 doi: 10.1016/B978-0-323-85765-9.00001-1
|
| 92 |
Nasim Saeidi, Hadi Goudarzvand, Hamed Mohammadi, Amirhossein Mardi, Shadi Ghoreishizadeh, Navid Shomali, Mahdi Goudarzvand. Dysregulation of miR-193a serves as a potential contributor to MS pathogenesis via affecting RhoA and Rock1. Multiple Sclerosis and Related Disorders 2023; 69: 104468 doi: 10.1016/j.msard.2022.104468
|
| 93 |
Hua Fan, Ruile Shen, Junqiang Yan, Yongjie Bai, Qizhi Fu, Xiaofei Shi, Ganqin Du, Dongmei Wang. Pyroptosis the Emerging Link Between Gut Microbiota and Multiple Sclerosis. Drug Design, Development and Therapy 2024; : 6145 doi: 10.2147/DDDT.S489454
|
| 94 |
Yujun Zeng, Zhiqian Li, Hongyan Zhu, Zhongwei Gu, Hu Zhang, Kui Luo. Recent Advances in Nanomedicines for Multiple Sclerosis Therapy. ACS Applied Bio Materials 2020; 3(10): 6571 doi: 10.1021/acsabm.0c00953
|
| 95 |
Lukasz Kalkowski, Piotr Walczak, Marcin P. Mycko, Izabela Malysz‐Cymborska. Reconsidering the route of drug delivery in refractory multiple sclerosis: Toward a more effective drug accumulation in the central nervous system. Medicinal Research Reviews 2023; 43(6): 2237 doi: 10.1002/med.21973
|
| 96 |
Zhila Maghbooli, Hesham Hosseinpour, Mohammad Reza Fattahi, Tarlan Varzandi, Sara Hamtaeigashi, Sara Mohammad-nabi, Yasaman Aghababaei, Mohammad Ali Sahraian. Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection. Multiple Sclerosis and Related Disorders 2022; 67: 104067 doi: 10.1016/j.msard.2022.104067
|
| 97 |
Saskia Maria Burm, Laura Anna Norma Peferoen, Ella Alwine Zuiderwijk-Sick, Krista Geraldine Haanstra, Bert Adriaan ‘t Hart, Paul van der Valk, Sandra Amor, Jan Bauer, Jeffrey John Bajramovic. Expression of IL-1β in rhesus EAE and MS lesions is mainly induced in the CNS itself. Journal of Neuroinflammation 2016; 13(1) doi: 10.1186/s12974-016-0605-8
|
| 98 |
Chloé Sieber, Deborah Chiavi, Christina Haag, Marco Kaufmann, Andrea B Horn, Holger Dressel, Chiara Zecca, Pasquale Calabrese, Caroline Pot, Christian Philipp Kamm, Viktor von Wyl. Electronic Health Diary Campaigns to Complement Longitudinal Assessments in Persons With Multiple Sclerosis: Nested Observational Study. JMIR mHealth and uHealth 2022; 10(10): e38709 doi: 10.2196/38709
|
| 99 |
Antonia Wenger, Pasquale Calabrese. Comparing underlying mechanisms of depression in multiple sclerosis and rheumatoid arthritis. Journal of Integrative Neuroscience 2021; 20(3) doi: 10.31083/j.jin2003081
|
| 100 |
Moussa A. Chalah, Samar S. Ayache. Deficits in Social Cognition: An Unveiled Signature of Multiple Sclerosis. Journal of the International Neuropsychological Society 2017; 23(3): 266 doi: 10.1017/S1355617716001156
|
| 101 |
Valeria Donisi, Alberto Gajofatto, Maria Angela Mazzi, Francesca Gobbin, Isolde Martina Busch, Annamaria Ghellere, Michela Rimondini. Insights for Fostering Resilience in Young Adults With Multiple Sclerosis in the Aftermath of the COVID-19 Emergency: An Italian Survey. Frontiers in Psychiatry 2021; 11 doi: 10.3389/fpsyt.2020.588275
|
| 102 |
Cristiana Pistono, Cecilia Osera, Chiara Boiocchi, Giulia Mallucci, Mariaclara Cuccia, Roberto Bergamaschi, Alessia Pascale. What’s new about oral treatments in Multiple Sclerosis? Immunogenetics still under question. Pharmacological Research 2017; 120: 279 doi: 10.1016/j.phrs.2017.03.025
|
| 103 |
Lara Gitto. Long Term Compliance for MS Patients in Treatment with Disease Modifying Drugs (DMDs). The Open Neurology Journal 2019; 13(1): 10 doi: 10.2174/1874205X01913010010
|
| 104 |
Rui Pedro Moura, Bruno Sarmento. Therapeutic Approaches toward Multiple Sclerosis: Where Do We Stand and Where Are We Headed?. Advanced Therapeutics 2019; 2(10) doi: 10.1002/adtp.201900070
|
| 105 |
Eiji Saito, Robert Kuo, Kevin R. Kramer, Nishant Gohel, David A. Giles, Bethany B. Moore, Stephen D. Miller, Lonnie D. Shea. Design of biodegradable nanoparticles to modulate phenotypes of antigen-presenting cells for antigen-specific treatment of autoimmune disease. Biomaterials 2019; 222: 119432 doi: 10.1016/j.biomaterials.2019.119432
|
| 106 |
Niloufar Salehi, Mitra Nourbakhsh, Shokoofe Noori, Hossein Rezaeizadeh, Afshin Zarghi. Tehranolid and Artemisinin Effects on Ameliorating Experimental Autoimmune Encephalomyelitis by Modulating Inflammation and Remyelination. Molecular Neurobiology 2023; 60(10): 5975 doi: 10.1007/s12035-023-03449-x
|
| 107 |
Francesco Patti, Clara Grazia Chisari, Emanuele D'Amico, Pietro Annovazzi, Paola Banfi, Roberto Bergamaschi, Raffaella Clerici, Marta Zaffira Conti, Antonio Cortese, Roberta Fantozzi, Mariano Fischetti, Maura Frigo, Maurizia Gatto, Paolo Immovilli, Stefania Leoni, Simona Malucchi, Giorgia Maniscalco, Girolama Alessandra Marfia, Damiano Paolicelli, Paola Perini, Carlo Serrati, Patrizia Sola, Rocco Totaro, Gabriella Turano, Paola Valentino, Mauro Zaffaroni, Cristina Zuliani, Diego Centonze. Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). Multiple Sclerosis and Related Disorders 2020; 42: 102124 doi: 10.1016/j.msard.2020.102124
|
| 108 |
Francesco Corallo, Carmela Rifici, Lilla Bonanno, Marcella Di Cara, Viviana Lo Buono, Giuseppe Venuti, Silvia Marino, Rosella Ciurleo, Viviana Torre, Giangaetano D’Aleo, Placido Bramanti, Edoardo Sessa. The role of teriflunomide in Multiple Sclerosis patient: an observational study. Psychology, Health & Medicine 2022; 27(10): 2204 doi: 10.1080/13548506.2021.1931371
|
| 109 |
Jan Hillert, Melinda Magyari, Per Soelberg Sørensen, Helmut Butzkueven, Anneke Van Der Welt, Sandra Vukusic, Maria Trojano, Pietro Iaffaldano, Fabio Pellegrini, Robert Hyde, Leszek Stawiarz, Ali Manouchehrinia, Tim Spelman. Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Frontiers in Neurology 2021; 12 doi: 10.3389/fneur.2021.647811
|
| 110 |
Úrsula Muñoz, Cristina Sebal, Esther Escudero, Elena Urcelay, Rafael Arroyo, Maria A. García-Martínez, Francisco J. Quintana, Roberto Álvarez-Lafuente, Maria Cruz Sádaba. Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-β. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-16218-y
|
| 111 |
Almudena Otálora-Alcaraz, Thomas Reilly, Martí Oró-Nolla, Melody Cui Sun, Lisa Costelloe, Hugh Kearney, Pabitra H. Patra, Eric J. Downer. The NLRP3 inflammasome: A central player in multiple sclerosis. Biochemical Pharmacology 2025; 232: 116667 doi: 10.1016/j.bcp.2024.116667
|
| 112 |
Kathiaja Miranda Souza, Isabela Maia Diniz, Lívia Lovato Pires de Lemos, Nélio Gomes Ribeiro Junior, Isabella de Figueiredo Zuppo, Juliana Alvares Teodoro, Francisco de Assis Acurcio, Álvaro Nagib Atallah, Augusto Afonso Guerra Júnior, Sreeram V. Ramagopalan. Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study. PLOS ONE 2020; 15(9): e0238476 doi: 10.1371/journal.pone.0238476
|
| 113 |
Alasdair J. Coles, Anat Achiron, Anthony Traboulsee, Barry A. Singer, Carlo Pozzilli, Celia Oreja-Guevara, Gavin Giovannoni, Giancarlo Comi, Mark S. Freedman, Tjalf Ziemssen, Debora Shiota, Andreea M. Rawlings, Alana T. Wong, Magdalena Chirieac, Xavier Montalban. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study. Therapeutic Advances in Neurological Disorders 2023; 16 doi: 10.1177/17562864231194823
|
| 114 |
Damiano Paolicelli, Alessia Manni, Antonio Iaffaldano, Maria Trojano. Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. CNS Drugs 2020; 34(1): 65 doi: 10.1007/s40263-019-00691-7
|
| 115 |
Roberto Bergamaschi, Livio Tronconi, Daniele Bosone, Antonella Mastretti, Laura Jommi, Marco Andrè Bassano, Renato Turrini, Sara Benati, Marco Volpe, Jean Marie Franzini, Silvia Allodi, Giulia Mallucci. Description and preliminary experience with Virtual Visit Assessment (ViVA) during the COVID-19 pandemic, a structured virtual management protocol for patients with multiple sclerosis. Neurological Sciences 2022; 43(2): 1207 doi: 10.1007/s10072-021-05371-3
|
| 116 |
Bart Van Wijmeersch, Barry A Singer, Aaron Boster, Simon Broadley, Óscar Fernández, Mark S Freedman, Guillermo Izquierdo, Jan Lycke, Carlo Pozzilli, Basil Sharrack, Brian Steingo, Heinz Wiendl, Sibyl Wray, Tjalf Ziemssen, Luke Chung, David H Margolin, Karthinathan Thangavelu, Patrick Vermersch. Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. Multiple Sclerosis Journal 2020; 26(13): 1719 doi: 10.1177/1352458519881759
|
| 117 |
Gemma Llufriu-Dabén, Alex Carrete, Elena Chierto, Jo Mailleux, Emeline Camand, Anne Simon, Tim Vanmierlo, Christiane Rose, Bernadette Allinquant, Jerome J.A. Hendriks, Charbel Massaad, Delphine Meffre, Mehrnaz Jafarian-Tehrani. Targeting demyelination via α-secretases promoting sAPPα release to enhance remyelination in central nervous system. Neurobiology of Disease 2018; 109: 11 doi: 10.1016/j.nbd.2017.09.008
|
| 118 |
Maha Haki, Haeder A. AL-Biati, Zahraa Salam Al-Tameemi, Inas Sami Ali, Hany A. Al-hussaniy. Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine 2024; 103(8): e37297 doi: 10.1097/MD.0000000000037297
|
| 119 |
Emma D. Deeks. Dimethyl Fumarate: A Review in Relapsing-Remitting MS. Drugs 2016; 76(2): 243 doi: 10.1007/s40265-015-0528-1
|
| 120 |
Michela Ada Noris Ferilli, Laura Papetti, Massimiliano Valeriani. Fingolimod in pediatric multiple sclerosis: three case reports. Neurological Sciences 2021; 42(S1): 19 doi: 10.1007/s10072-021-05076-7
|
| 121 |
Samuel Lees, Mathew Dicker, Jie En Ku, Varun Chaganti, Matthew Mew-Sum, Nick Wang, Angela Smith, Christopher Oldmeadow, Wooi Lynn Goon, Marc Bevan, Danielle Lang, Madeleine Hinwood. Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing–remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis. BMJ Open 2021; 11(11): e051509 doi: 10.1136/bmjopen-2021-051509
|
| 122 |
Kristin A Johnson, Victoria M Bandera, Manfred Diehl, Heather J Leach, Brett W Fling. Walking performance differs between people with multiple sclerosis who perform distinct types of exercise. Neurodegenerative Disease Management 2024; 14(3-4): 75 doi: 10.1080/17582024.2024.2389037
|
| 123 |
Zuber Khan, Ghanshyam Das Gupta, Sidharth Mehan. Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges. Journal of Clinical Medicine 2023; 12(13): 4274 doi: 10.3390/jcm12134274
|
| 124 |
LARA GITTO.
Multiple Sclerosis: Perspectives in Treatment and Pathogenesis
. 2017; : 17 doi: 10.15586/codon.multiplesclerosis.2017.ch2
|
| 125 |
Alasdair J. Coles, Douglas L. Arnold, Ann D. Bass, Aaron L. Boster, D. Alastair S. Compston, Óscar Fernández, Eva Kubala Havrdová, Kunio Nakamura, Anthony Traboulsee, Tjalf Ziemssen, Alan Jacobs, David H. Margolin, Xiaobi Huang, Nadia Daizadeh, Madalina C. Chirieac, Krzysztof W. Selmaj. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Therapeutic Advances in Neurological Disorders 2021; 14 doi: 10.1177/1756286420982134
|
| 126 |
Patrick Vermersch, Jérôme De Sèze, Pierre Clavelou, Françoise Durand-Dubief, Elisabeth Maillart, Claude Mekies, Thibault Moreau, Caroline Papeix, Ayman Tourbah, Pierre Labauge. Expert opinion: Criteria for second-line treatment failure in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders 2019; 36: 101406 doi: 10.1016/j.msard.2019.101406
|
| 127 |
Chynna-Loren Sheremeta, Sai Yarlagadda, Mark L. Smythe, Peter G. Noakes. Prostaglandins in the Inflamed Central Nervous System: Potential Therapeutic Targets. Current Drug Targets 2024; 25(13): 885 doi: 10.2174/0113894501323980240815113851
|
| 128 |
Analisa Jia, Lisa Kuramoto, Amir Khakban, Weng Sut Sio, Anthony Traboulsee, M A De Vera, Jiwon Oh, Jonathan Loree, Roger Tam, Larry D Lynd, Jacquelyn J Cragg. Fingolimod and risk of skin cancer among individuals with multiple sclerosis: a population-based cohort study protocol. BMJ Open 2025; 15(1): e088924 doi: 10.1136/bmjopen-2024-088924
|
| 129 |
Gianluca Quaranta, Alessandra Guarnaccia, Giovanni Fancello, Chiara Agrillo, Federica Iannarelli, Maurizio Sanguinetti, Luca Masucci. Fecal Microbiota Transplantation and Other Gut Microbiota Manipulation Strategies. Microorganisms 2022; 10(12): 2424 doi: 10.3390/microorganisms10122424
|
| 130 |
Kait F. Al, Laura J Craven, Shaeley Gibbons, Seema Nair Parvathy, Ana Christina Wing, Chantelle Graf, Kate A Parham, Steven M Kerfoot, Hannah Wilcox, Jeremy P Burton, Marcelo Kremenchutzky, Sarah A Morrow, Courtney Casserly, Jon Meddings, Manas Sharma, Michael S. Silverman. Fecal microbiota transplantation is safe and tolerable in patients with multiple sclerosis: A pilot randomized controlled trial. Multiple Sclerosis Journal - Experimental, Translational and Clinical 2022; 8(2) doi: 10.1177/20552173221086662
|
| 131 |
Gabriel Pardo, David E. Jones. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. Journal of Neurology 2017; 264(12): 2351 doi: 10.1007/s00415-017-8594-9
|
| 132 |
Patrick Vermersch, Jiwon Oh, Mark Cascione, Celia Oreja-Guevara, Claudio Gobbi, Lori H. Travis, Kjell-Morten Myhr, Patricia K. Coyle. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. Multiple Sclerosis and Related Disorders 2020; 43: 102158 doi: 10.1016/j.msard.2020.102158
|
| 133 |
A. Manzano, I. Eskyté, H.L. Ford, S.H. Pavitt, B. Potrata, K. Schmierer, J. Chataway, E.J.D. Webb, D. Meads, G. Pepper, H.L. Bekker. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 2020; 46: 102507 doi: 10.1016/j.msard.2020.102507
|
| 134 |
Indu Etta, Ruaa Elballushi, Viktoriia Kolesnyk, Kim P Sia, Sana Rehman, Sehrish Arif, Sania J Moonnumackel, Arun Nair. Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis. Cureus 2023; doi: 10.7759/cureus.45454
|
| 135 |
Bruno M. Barros, Marcelo G. Correia, Bernardo R. Tura, Carlos S. Magliano. Cost-Utility Analysis and Efficiency Frontier of Drugs Available in Brazil for the Treatment of Relapsing-Remitting Multiple Sclerosis. Value in Health Regional Issues 2025; 48: 101092 doi: 10.1016/j.vhri.2025.101092
|
| 136 |
Alena Sorensen, Devon S. Conway, Farren B.S. Briggs. Characterizing relapsing remitting multiple sclerosis patients burdened with hypertension, hyperlipidemia, and asthma. Multiple Sclerosis and Related Disorders 2021; 53: 103040 doi: 10.1016/j.msard.2021.103040
|
| 137 |
Omar Deeb, Maisa Nabulsi. Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study. Current Topics in Medicinal Chemistry 2020; 20(26): 2391 doi: 10.2174/1568026620666200924114827
|
| 138 |
Francesco Saccà, Roberta Lanzillo, Alessio Signori, Giorgia T Maniscalco, Elisabetta Signoriello, Salvatore Lo Fermo, Annamaria Repice, Pietro Annovazzi, Damiano Baroncini, Marinella Clerico, Eleonora Binello, Raffaella Cerqua, Giorgia Mataluni, Simona Bonavita, Luigi Lavorgna, Ignazio Roberto Zarbo, Alice Laroni, Silvia Rossi, Lorena Pareja Gutierrez, Sara La Gioia, Barbara Frigeni, Valeria Barcella, Jessica Frau, Eleonora Cocco, Giuseppe Fenu, Valentina Torri Clerici, Arianna Sartori, Sarah Rasia, Cinzia Cordioli, Alessia Di Sapio, Simona Pontecorvo, Roberta Grasso, Caterina Barrilà, Cinzia Valeria Russo, Sabrina Esposito, Domenico Ippolito, Francesca Bovis, Fabio Gallo, Maria Pia Sormani. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study. Multiple Sclerosis Journal 2019; 25(9): 1263 doi: 10.1177/1352458518790390
|
| 139 |
Francesco Patti, Clara Grazia Chisari, Simona Toscano, Pietro Annovazzi, Paola Banfi, Roberto Bergamaschi, Raffaella Clerici, Marta Zaffira Conti, Antonio Cortese, Roberta Fantozzi, Diana Ferraro, Mariano Fischetti, Maura Frigo, Maurizia Gatto, Paolo Immovilli, Stefania Leoni, Simona Malucchi, Giorgia Maniscalco, Girolama Alessandra Marfia, Damiano Paolicelli, Paola Perini, Carlo Serrati, Rocco Totaro, Gabriella Turano, Paola Valentino, Mauro Zaffaroni, Cristina Zuliani, Diego Centonze. Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH study. Multiple Sclerosis and Related Disorders 2023; 70: 104474 doi: 10.1016/j.msard.2022.104474
|
| 140 |
Malak Al-Mojel, Raed Alroughani, Texy Kannankeril, Mohammed Dashti, Rabeah Al-Temaimi. GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients. Multiple Sclerosis and Demyelinating Disorders 2019; 4(1) doi: 10.1186/s40893-019-0039-0
|
| 141 |
Huah Shin Ng, Feng Zhu, Elaine Kingwell, Yinshan Zhao, Shenzhen Yao, Okechukwu Ekuma, Lawrence W Svenson, Charity Evans, John D. Fisk, Ruth Ann Marrie, Helen Tremlett. Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. Expert Review of Neurotherapeutics 2021; 21(1): 131 doi: 10.1080/14737175.2021.1847085
|
| 142 |
Ed Waddingham, Paul M. Matthews, Deborah Ashby. Exploiting relationships between outcomes in Bayesian multivariate network meta‐analysis with an application to relapsing‐remitting multiple sclerosis. Statistics in Medicine 2020; 39(24): 3329 doi: 10.1002/sim.8668
|
| 143 |
Jiří Piťha. Strategy initiation of treatment for multiple sclerosis. Neurologie pro praxi 2016; 17(4): 236 doi: 10.36290/neu.2016.049
|
| 144 |
Olivia Wills, Yasmine Probst, Jodi Haartsen, Anne‐Therese McMahon. The role of multidisciplinary MS care teams in supporting lifestyle behaviour changes to optimise brain health among people living with MS: A qualitative exploration of clinician perspectives. Health Expectations 2024; 27(2) doi: 10.1111/hex.14042
|
| 145 |
Syed A. Rizvi, Joshua A. Stone, Saima T. Chaudhry, Nichola Haddad, Brian Wong, Jennifer O. Grimes. Clinical Neuroimmunology. Current Clinical Neurology 2020; : 159 doi: 10.1007/978-3-030-24436-1_8
|
| 146 |
G. Dalla Costa, L. Leocani, G. Comi. Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis. Expert Review of Clinical Immunology 2022; 18(2): 105 doi: 10.1080/1744666X.2022.2031982
|
| 147 |
Grace Lassiter, Carlie Melancon, Tyler Rooney, Anne-Marie Murat, Jessica S. Kaye, Adam M. Kaye, Rachel J. Kaye, Elyse M. Cornett, Alan D. Kaye, Rutvij J. Shah, Omar Viswanath, Ivan Urits. Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Neurology International 2020; 12(3): 89 doi: 10.3390/neurolint12030016
|
| 148 |
Andrés Barboza. Suspensión de las terapias modificadoras de la enfermedad en esclerosis múltiple. Una aproximación multidimensional. Neurología Argentina 2018; 10(4): 232 doi: 10.1016/j.neuarg.2018.08.002
|
| 149 |
Mehdi Rezaee, Sadegh Izadi, Khosro Keshavarz, Afshin Borhanihaghighi, Ramin Ravangard. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran. Journal of Medical Economics 2019; 22(4): 297 doi: 10.1080/13696998.2018.1560750
|
| 150 |
Rachael McCool, Katy Wilson, Mick Arber, Kelly Fleetwood, Sydney Toupin, Howard Thom, Iain Bennett, Susan Edwards. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders 2019; 29: 55 doi: 10.1016/j.msard.2018.12.040
|
| 151 |
Kiyoon Min, Abhishek Sahu, Sae Hyun Jeon, Giyoong Tae. Emerging drug delivery systems with traditional routes – A roadmap to chronic inflammatory diseases. Advanced Drug Delivery Reviews 2023; 203: 115119 doi: 10.1016/j.addr.2023.115119
|
| 152 |
Birsen Can Demirdöğen. A literature review of biosensors for multiple sclerosis: Towards personalized medicine and point-of-care testing. Multiple Sclerosis and Related Disorders 2021; 48: 102675 doi: 10.1016/j.msard.2020.102675
|
| 153 |
Omid Jamshidi Kandjani, Shadi Yaqoubi, Samad Shams Vahdati, Behnam Borhannejad, Siavoush Dastmalchi, Ali Akbar Alizadeh. S1PR1 modulators in multiple sclerosis: Efficacy, safety, comparison, and chemical structure insights. European Journal of Medicinal Chemistry 2023; 250: 115182 doi: 10.1016/j.ejmech.2023.115182
|
| 154 |
Sven Günther, Paolo Fagone, Gaël Jalce, Atanas G. Atanasov, Christophe Guignabert, Ferdinando Nicoletti. Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets. Drug Discovery Today 2019; 24(2): 428 doi: 10.1016/j.drudis.2018.11.003
|
| 155 |
Solange M. Saxby, Mary A. Ehlinger, Lisa Brooks, Tyler J. Titcomb, Patrick Ten Eyck, Linda M. Rubenstein, Babita Bisht, Farnoosh Shemirani, Christine Gill, John Kamholtz, Linda G. Snetselaar, Terry L. Wahls. Feasibility and assessment of self-reported dietary recalls among newly diagnosed multiple sclerosis: a quasi-experimental pilot study. Frontiers in Nutrition 2024; 11 doi: 10.3389/fnut.2024.1369700
|
| 156 |
Qiangguo Gao, Yi Zhang, Chaofeng Han, Xiang Hu, Hua Zhang, Xiongfei Xu, Jun Tian, Yiqi Liu, Yuanyuan Ding, Juan Liu, Chunmei Wang, Zhenhong Guo, Yongguang Yang, Xuetao Cao. Blockade of CD47 ameliorates autoimmune inflammation in CNS by suppressing IL-1-triggered infiltration of pathogenic Th17 cells. Journal of Autoimmunity 2016; 69: 74 doi: 10.1016/j.jaut.2016.03.002
|
| 157 |
Marcos Vasquez, Marta Consuegra-Fernández, Fernando Aranda, Aitor Jimenez, Shirley Tenesaca, Myriam Fernandez-Sendin, Celia Gomar, Nuria Ardaiz, Claudia Augusta Di Trani, Noelia Casares, Juan Jose Lasarte, Francisco Lozano, Pedro Berraondo. Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-α. The Journal of Immunology 2019; 203(3): 696 doi: 10.4049/jimmunol.1801462
|
| 158 |
Fatema Bhinderwala, Heidi E. Roth, Mary Filipi, Samantha Jack, Robert Powers. Potential Metabolite Biomarkers of Multiple Sclerosis from Multiple Biofluids. ACS Chemical Neuroscience 2024; 15(6): 1110 doi: 10.1021/acschemneuro.3c00678
|
| 159 |
Josef Jampílek, Katarína Kráľová, Petr Novák, Michal Novák. Nanobiotechnology in Neurodegenerative Diseases. 2019; : 65 doi: 10.1007/978-3-030-30930-5_4
|
| 160 |
Hilary Gunn, Jackie Andrade, Lorna Paul, Linda Miller, Siobhan Creanor, Kara Stevens, Colin Green, Paul Ewings, Andrew Barton, Margie Berrow, Jane Vickery, Ben Marshall, John Zajicek, Jennifer Freeman. A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT. Health Technology Assessment 2019; 23(27): 1 doi: 10.3310/hta23270
|
| 161 |
Isabel Sánchez-Vera, Esther Escudero, Úrsula Muñoz, María C. Sádaba. IgM to phosphatidylcholine in multiple sclerosis patients: from the diagnosis to the treatment. Therapeutic Advances in Neurological Disorders 2023; 16 doi: 10.1177/17562864231189919
|
| 162 |
Gabriel Bsteh, Harald Hegen, Carolin Dosser, Michael Auer, Klaus Berek, Sebastian Wurth, Anne Zinganell, Franziska Di Pauli, Florian Deisenhammer, Thomas Berger. To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders 2020; 39: 101908 doi: 10.1016/j.msard.2019.101908
|
| 163 |
Maria Cecilia Vieira, Yunfeng Li, Xiangyi Meng, Huanxue Zhou, Olivia Wenxian Piao, Christen Kutz, Devon Conway. Impact of Switching to Fingolimod Versus Injectable Disease-Modifying Therapy Cycling on Risk of Multiple Sclerosis–Related Relapses. International Journal of MS Care 2021; 23(2): 73 doi: 10.7224/1537-2073.2019-050
|
| 164 |
Thais F.C. Fraga‐Silva, Luiza A.N. Mimura, Sofia F.G. Zorzella‐Pezavento, Larissa L.W. Ishikawa, Thais G.D. França, Rodolfo Thomé, Liana Verinaud, Maria S.P. Arruda, Alexandrina Sartori. Tolerogenic Vaccination with MOG/VitD Overcomes Aggravating Effect of C. albicans in Experimental Encephalomyelitis. CNS Neuroscience & Therapeutics 2016; 22(10): 807 doi: 10.1111/cns.12572
|
| 165 |
Cristina Scavone, Valerio Liguori, Olusola Jephthah Adungba, Daniele Di Giulio Cesare, Maria Giuseppa Sullo, Vincenzo Andreone, Liberata Sportiello, Giorgia Teresa Maniscalco, Annalisa Capuano. Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series. Frontiers in Neurology 2024; 15 doi: 10.3389/fneur.2024.1386527
|
| 166 |
Larissa Ragozo Cardoso de Oliveira, Luiza Ayumi Nishiyama Mimura, Thais Fernanda de Campos Fraga-Silva, Larissa Lumi Watanabe Ishikawa, Ana Angélica Henrique Fernandes, Sofia Fernanda Gonçalves Zorzella-Pezavento, Alexandrina Sartori. Calcitriol Prevents Neuroinflammation and Reduces Blood-Brain Barrier Disruption and Local Macrophage/Microglia Activation. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.00161
|
| 167 |
Elizabeth Regina Comini-Frota, Cláudia C. F. Vasconcelos, Maria Fernanda Mendes. Guideline for multiple sclerosis treatment in Brazil: Consensus from the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology. Arquivos de Neuro-Psiquiatria 2017; 75(1): 57 doi: 10.1590/0004-282x20160185
|
| 168 |
Shitiz Sriwastava, Katherine Beard, Suban Amatya, Kriti Shrestha, Shruti Jaiswal, Robert P. Lisak. Clinical Aspects of Multiple Sclerosis Essentials and Current Updates. 2024; : 135 doi: 10.1016/B978-0-323-95343-6.00014-5
|
| 169 |
Tsen-Hsuan Lin, Jie Zhan, Chunyu Song, Michael Wallendorf, Peng Sun, Xuan Niu, Ruimeng Yang, Anne H. Cross, Sheng-Kwei Song. Diffusion Basis Spectrum Imaging Detects Axonal Loss After Transient Dexamethasone Treatment in Optic Neuritis Mice. Frontiers in Neuroscience 2021; 14 doi: 10.3389/fnins.2020.592063
|
| 170 |
Alan D Kaye, John Lacey, Viet Le, Ahmed Fazal, Nicole A Boggio, Dorothy H Askins, Lillian Anderson, Christopher L Robinson, Antonella Paladini, Chizoba N Mosieri, Adam M Kaye, Shahab Ahmadzadeh, Sahar Shekoohi, Giustino Varrassi. The Evolving Role of Monomethyl Fumarate Treatment as Pharmacotherapy for Relapsing-Remitting Multiple Sclerosis. Cureus 2024; doi: 10.7759/cureus.57714
|
| 171 |
Cody D. Moorman, Alan D. Curtis, Alexander G. Bastian, Sarah E. Elliott, Mark D. Mannie. A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4+ CD25high FOXP3+ Regulatory T Cells in Myelin-Specific TCR Transgenic Mice Contingent Upon Low-Efficiency T Cell Antigen Receptor Recognition. Frontiers in Immunology 2019; 9 doi: 10.3389/fimmu.2018.03119
|
| 172 |
Fiorenzo Santoleri, Ruggero Lasala, Eleononora Berardini, Flavia Vernacchio, Donato Leo, Alberto Costantini. Adherence, Persistence, Switching and Costs of Injectable and Oral Therapies for Multiple Sclerosis. Real Life Analysis Over 6 Years of Treatment. Hospital Pharmacy 2024; 59(4): 476 doi: 10.1177/00185787241232615
|
| 173 |
Minodora Dobreanu, Doina Ramona Manu, Ion Bogdan Mănescu, Manuela Rozalia Gabor, Adina Huţanu, Laura Bărcuţean, Rodica Bălaşa. Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients – An In Vitro Study. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.743010
|
| 174 |
Janne Verreycken, Paulien Baeten, Bieke Broux. Regulatory T cell therapy for multiple sclerosis: Breaching (blood-brain) barriers. Human Vaccines & Immunotherapeutics 2022; 18(7) doi: 10.1080/21645515.2022.2153534
|
| 175 |
Grace Minassian. PharmacotherapyFirst: A Multimedia Learning Resource. 2017; doi: 10.21019/pharmacotherapyfirst.ms_overview
|
| 176 |
O. M. Rønning, K. D. Tornes. Need for symptomatic management in advanced multiple sclerosis. Acta Neurologica Scandinavica 2017; 135(5): 529 doi: 10.1111/ane.12631
|
| 177 |
David Haschka, Piotr Tymoszuk, Gabriel Bsteh, Verena Petzer, Klaus Berek, Igor Theurl, Thomas Berger, Günter Weiss. Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.00594
|
| 178 |
Farren B.S. Briggs, Nicolas R. Thompson, Devon S. Conway. Prognostic factors of disability in relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 2019; 30: 9 doi: 10.1016/j.msard.2019.01.045
|
| 179 |
Aiora Ostolaza, Jon Corroza, Teresa Ayuso. Multiple sclerosis and aging: comorbidity and treatment challenges. Multiple Sclerosis and Related Disorders 2021; 50: 102815 doi: 10.1016/j.msard.2021.102815
|
| 180 |
Faizan Ahmad, Upasana Pathak, Abhichandan Das, Anusri Dhar. Update on Promising Biomarkers for Multiple Sclerosis. The Journal of Neurobehavioral Sciences 2021; 8(1): 17 doi: 10.4103/jnbs.jnbs_40_20
|
| 181 |
Fredrik N. Albach, Christian Geier, Christian Keicher, Maximilian G. Posch, Stephan J. Schreiber, Gerald Grütz, Levent Akyüz, Xiaodong Luo, Annaig Le-Halpere, Philippe Truffinet, Frank Wagner. Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis. Neurology and Therapy 2024; 13(6): 1607 doi: 10.1007/s40120-024-00659-w
|
| 182 |
Hamza Coban, Areeba Siddiqui, Marina A. Creed, Wijdan Rai, Jaime Imitola. Preventive neurology concepts for training the next-generation and closing gaps in real-world Multiple Sclerosis Care. Multiple Sclerosis and Related Disorders 2021; 47: 102631 doi: 10.1016/j.msard.2020.102631
|
| 183 |
Roberto De Masi, Stefania Orlando. GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35. Pharmaceuticals 2021; 14(11): 1195 doi: 10.3390/ph14111195
|